Cipla Ltd - 500087 - Update On USFDA Inspection At Invagen Manufacturing Facility In Hauppauge, Long Island, New York, USA
Cipla's wholly-owned subsidiary, InvaGen Pharmaceuticals Inc., received an Establishment Inspection Report (EIR) from the USFDA, confirming the closure of the inspection at its Hauppauge, New York manufacturing facility. This positive outcome removes regulatory uncertainty.
Aug 04 2026 08:58:49
Cipla Ltd - 500087 - Cipla Receives U.S. FDA Approval For Generic Advair Diskus®
Cipla received U.S. FDA approval for Generic Advair Diskus® in all three strengths, a treatment for asthma and COPD. This approval opens access to an estimated $908 million U.S. market, with launch anticipated in Q2 FY2026-27.
Jul 27 2026 22:54:54
Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Cipla announced its Q1 FY27 unaudited consolidated financial results. The company reported revenue of Rs.7,119 crore, a 2% increase YoY, but net profit declined by 39% YoY to Rs.789 crore. EBITDA margin stood at 16.7%, down from 25.6% in Q1 FY26.
Jul 23 2026 12:39:38
Cipla Ltd - 500087 - USFDA Inspection At Invagen Manufacturing Facility In Central Islip, Long Island, NY, USA
Cipla's wholly-owned subsidiary, InvaGen Pharmaceuticals Inc., received one inspectional observation in Form 483 from the USFDA. This followed a routine cGMP inspection of its Central Islip, NY manufacturing facility from July 13-17, 2026. The company committed to addressing the observation.
Jul 18 2026 09:33:48
Cipla Ltd - 500087 - Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Cipla received ESG ratings 'Crisil ESG 69' and 'Crisil Core ESG 66' from Crisil ESG Ratings & Analytics Limited on its environmental, social, and governance performance. This independent assessment provides transparency on the company's sustainability practices.
Jul 12 2026 11:26:46
Read More